Strategies for preventing mucosal cell-Associated HIV Transmission

Journal of Infectious Diseases

Volumn 210, Issue , 2014, Pages S674-S680

  Whaley, Kevin J ^a   Mayer, Kenneth H ^b  

^a Mapp Biopharmaceutical   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antibodies.; Antiretrovirals; Cell Associated transmission; HIV vaccines

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ANIMAL; FEMALE; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MALE; MUCOSA; PASSIVE IMMUNIZATION; PHYSIOLOGY; TRANSMISSION; VIROLOGY;

AIDS VACCINES; ANIMALS; ANTI-HIV AGENTS; FEMALE; HIV; HIV INFECTIONS; HUMANS; IMMUNIZATION, PASSIVE; MALE; MUCOUS MEMBRANE;

EID: 84925223740     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu398     Document Type: Article

References (61)

1. UNAIDS. Global AIDS response progress reporting 2014: construction of core indicators for monitoring the 2011 UN political declaration on HIV/AIDS. Geneva, Switzerland: UNAIDS, 2014.
2. Anderson DJ, Politch JA, Nadolski AM, Blaskewicz CD, Pudney J, Mayer KH. Targeting Trojan Horse leukocytes for HIV prevention. AIDS 2010; 24:163-87.
3. Tsai CC, Emau P, Follis KE, et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 1998; 72:4265-73.
4. Cohen MS, Chen YQ, McCauleyM, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
5. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-99.
6. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399-410.
7. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): A randomised, double-blind, placebocontrolled phase 3 trial. Lancet 2013; 381:2083-90.
8. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367:423-34.
9. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012; 367:411-22.
10. Marrazzo J, Ramjee G, Nair G. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine or vaginal tenofovir gel in the VOICE study [abstract MTN 003]. Presented at: 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, Georgia, 2013.
11. Anderson PL, Glidden DV, Liu A, et al. For the iPrEx Study T. Emtricitabine-Tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med 2012; 4:151ra125.
12. Romano J, Variano B, Coplan P, et al. Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. AIDS Res Hum Retroviruses 2009; 25:483-8.
13. International Partnership for Microbicides. http://www.ipm.org. Accessed 26 March 2014.
14. Spreen W, Williams P, Margolis D, et al. First study of repeat dose coadministration of GSK1265744 and TMC278 long-Acting parenteral nanosuspensions: pharmacokinetics, safety and tolerability in healthy adults. Presented at: 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Kuala Lumpur, Malaysia, 2013.
15. Duncan CJ, Williams JP, Schiffner T, et al. High-multiplicity HIV-1 infection and neutralizing antibody evasion mediated by the macrophage-T cell virological synapse. J Virol 2014; 88:2025-34.
16. Sigal A, Kim JT, Balazs AB, et al. Cell-To-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 2011; 477: 95-8.
17. Titanji BK, Aasa-Chapman M, Pillay D, Jolly C. Protease inhibitors effectively block cell-To-cell spread of HIV-1 between T cells. Retrovirology, 2013; 10:161.
18. Permanyer M, Ballana E, Ruiz A, et al. Antiretroviral agents effectively block HIV replication after cell-To-cell transfer. J Virol 2012; 86:8773-80.
19. Perno CF, Svicher V, Schols D, Pollicita M, Balzarini J, Aquaro S. Therapeutic strategies towards HIV-1 infection in macrophages. Antiviral Res 2006; 71:293-300.
20. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-74.
21. Mayer KH, Venkatesh KK. Interactions of HIV, other sexually transmitted diseases, and genital tract inflammation facilitating local pathogen transmission and acquisition. Am J Reprod Immunol 2011; 65: 308-16.
22. Cohen MS, Muessig KE, Smith MK, Powers KA, Kashuba AD. Antiviral agents and HIV prevention: controversies, conflicts, and consensus. AIDS 2012; 26:1585-98.
23. Thompson CG, Cohen MS, Kashuba AD. Antiretroviral pharmacology in mucosal tissues. J Acquir Immune Defic Syndr 2013; 63(suppl 2): S240-247.
24. Sheth PM, Kovacs C, Kemal KS, et al. Persistent HIV RNA shedding in semen despite effective antiretroviral therapy. AIDS 2009; 23:2050-4.
25. Lambert-Niclot S, Tubiana R, Beaudoux C, et al. Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma on a 2002-2011 survey. AIDS 2012; 26:971-5.
26. Politch JA, Mayer KH, Welles SL, et al. Highly active antiretroviral therapy does not completely suppress HIV in semen of sexually active HIVinfected men who have sex with men. AIDS 2012; 26:1535-43.
27. Naranbhai V, Abdool Karim SS, Altfeld M, et al. Innate immune activation enhances HIV acquisition in women, diminishing the effectiveness of tenofovir microbicide gel. J Infect Dis 2012; 206:993-1001.
28. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-20.
29. Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366:1275-86.
30. Chung AW, Ghebremichael M, Robinson H, et al. Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci Trans Med 2014; 6:228ra38.
31. Yates NL, Liao H-X, Fong Y, et al. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Trans Med 2014; 6:228ra39.
32. Mascola JR, Lewis MG, Stiegler G, et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999; 73:4009-18.
33. Hessell AJ, Poignard P, Hunter M, et al. Effective, low-Titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 2009; 15:951-4.
34. Hessell AJ, Rakasz EG, Tehrani DM, et al. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosla challenge by simian-human immunodeficiency virus SHIV Ba-L. J Virol 2010; 84:1302-13.
35. Hur EM, Patel SN, Shimizu S, et al. Inhibitory effect of HIV-specific neutralizing IgA on mucosal transmission of HIV in humanized mice. Blood 2012; 120:4571-82.
36. Watkins JD, Sholukh AM, Mukhtar MM, et al. Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission. AIDS 2013; 27:F13-20.
37. Malbec M, Porrot F, Rua R, et al. Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission. J Exp Med 2013; 210: 2813-21.
38. Zalevsky J, Chamberlain AK, Horton HM, et al. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 2010; 28:157-9.
39. Global Vaccine Enterprise. Prevention trials in the population of infants born to HIV-infected mothers: meeting report. http://www. vaccineenterprise.org/content/prevention-Trials-infants. Accessed 24 July 2014.
40. Balazs AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D. Antibodybased protection against HIV infection by vectored immunoprophylaxis. Nature 2012; 481:81-4.
41. Abdel-Motal UM, Sarkis PT, Han T, et al. Anti-gp120 minibody gene transfer to female genital epithelial cells protects against HIV-1 virus challenge in vitro. PLoS One 2011; 6:e26473.
42. Balazs AB, Ouyanga Y, Hong CM, et al. Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. Nat Med 2014; 20:296-300.
43. Klein F, Halper-Stromberg A, Horwitz JA, et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 2012; 492:118-22.
44. Harrison PF, Hemmerling A, Romano J, Whaley KJ, Young Holt B. Developing multipurpose reproductive health technologies: An integrated strategy. AIDS Res Treat 2013; 2013:790154.
45. Whaley KJ, Zeitlin L. Antibody-based concepts for multipurpose prevention technologies. Antivir Res 2013; 100:S48-53.
46. Zhu P, Chertova E, Bess J, et al. Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virions. Proc Nat Acad Sci U S A 2003; 100:15812-17.
47. Lawn SD, Roberts BD, Griffin GE, Folks TM, Butera ST. Cellular compartments of HIV1 replication: determination by virion-Associated host proteins and the impact of opportunistic infection in vivo. J Virol 2000; 74:139-45.
48. Berre SmGaudin R, Cunha de Alencar B, DesdouitsM, et al. CD36-specific antibodies block release of HIV-1 from infected primary macrophages and its transmission to T cells. J Exp Med 2003; 210:2523-38.
49. Bounou S, Giguere J-F, Cantin R, et al. The importance of virus-Associated host ICAM-1 in human immunodeficiency virus type 1 dissemination depends on the cellular context. FASEB J 2004; 18:1294-6.
50. Olinger GG, Saifuddin M, Spear GT. CD4-negative cells bind human immunodeficiency virus type 1 and efficiently transfer virus to T cells. J Virol 2000; 74:8550-7.
51. Diaz L, Mao H, Zhou Y, et al. TSG101 exposure on the surface of HIV-1 infected cells: implications for monoclonal antibody therapy for HIV/AIDS. Am J Transl Res 2010; 2:368-80.
52. Puryear WB, Yu X, Ramiraez NP, Reinhard BM, Gummuluru S. HIV incorporation of host-cell-derived glycosphingolipid GM3 allows for capture by mature dendritic cells. Proc Nat Acad Sci U S A 2012; 109:7475-80.
53. Puryear WB, Akiyama H, Geer SD, et al. Interferon-inducible mechanism of dendritic cell-mediated HIV-1 disseminataion is dependent on Siglec-1/CD169. PLoS Path 2013; 9:e1003291.
54. Chancey CJ, Khanna KV, Seegers JFML, et al. Lactobacilli-expressed single-chain variable fragment (scFv) specific for intercellular adhesion molecule 1 (ICAM-1) blocks cell-Associated HIV-1 transmission across a ceervical epithelial monolayer. J Immun 2006; 176:5617-36.
55. Cone RA, Whaley KJ. Monoclonal antibodies for reproductive health: Part I. Preventing sexual transmission of disease and pregnancy with topically applied antibodies. Am J Reprod Immunol 1994; 32:114-31.
56. Wang Y-Y, Kannan A, Nunn KL, et al. IgG in cervicovaginal mucus traps HSV and prevents vaginal Herpes infections. [Epub ahead of print]. Muc Immun 2014; doi: 10.1038/mi.2013.120.
57. Diekman AB, Norton EJ, Westbrook VA, Klotz KL, Naaby-Hansen S, Herr JC. Anti-sperm antibodies from infertile patients and their cognate sperm antigens: A review. Identity between SAGA-1, the H6-3C4 antigen, and CD52. Am J Reprod Immunol 2000; 43:134-43.
58. Kirchhoff C, Schroter S. New insights into the origin, structure and role of CD52: A major component of the mammalian sperm glycocalyx. Cell Tis Org 2001; 168:93-104.
59. Whaley KJ, Hiatt A, Zeitlin L. Emerging antibody products and Nicotiana manufacturing. Hum Vac 2011; 7:349-56.
60. Excler J-L, Ake J, Robb ML, Kim JH, Plotkin SA. Nonneutralizing functional antibodies: A new old paradigm for HIV vaccines. Clin Vac Immun 2014; 21:1023-1036.
61. Salle B, Brochard P, Bourry O, et al. Infection of macaques after vaginal exposure to cell-Associated simian immunodeficiency virus. J Infect Dis 2010; 202:337-44.